Расширенный поиск

Лечение атопического дерматита у детей: акцент на профилактику и восстановление эпидермального барьера

Полный текст:


В статье представлены эволюция взглядов на этиопатогенез заболевания и изменившиеся подходы к лечению детей с атопическим дерматитом. Изложены основные механизмы этиопатогенеза атопического дерматита, влияние липидзамещающей терапии на воспаление и восстановление функции эпидермиса, даны рекомендации по уходу за кожей детей с атопическим дерматитом, правила выбора и особенности применения эмоллиентов у детей. Интересны исследования о влиянии состава микробиома кожи на становление барьерной функции кожи и формирование иммунного равновесия, представлен современный взгляд на профилактическое и терапевтическое применение пробиотических штаммов.

Об авторе

Н. Д. Титова
Белорусская медицинская академия последипломного образования


Список литературы

1. Wollenberg A. (2018) Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. JEADV, vol. 32, no 5, pp. 657–682.

2. Wollenberg A. (2018) Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. JEADV, vol. 32, no 6, pp. 850–878.

3. Baranov A. (2016) Federal clinical recommendations for the provision of medical care for children with atopic eczema. Moscov: union of Pediatricians of Russia. (in Russian) Available at: (Accessed June 26, 2018).

4. Bianchi P., Theunis J., Casas C. (2016) Effects of a new emollient-based treatment on skin microflora balance and barrier function in children with mild atopic dermatitis. Pediatr Dermatol., vol. 33, pp. 165–171.

5. Elias P.M., Wakefeld J.S., Man M.Q. (2019) Moisturizers versus current and next-generation barrier repair therapy for the management of atopic dermatitis. Skin Pharmacol Physiol., vol. 32(1), pp. 1–7. doi: 10.1159/000493641.

6. Elias P.M. (2007) The skin barrier as an innate immune element. Semin Immunopathol., vol. 29(1), pp. 3–14.

7. Schmuth M., Haqq C.M., Cairns W.J., Holder J.C. (2004) Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol., vol. 122(4), pp. 971–83.

8. Danby S.G., Brown K., Higgs-Bayliss T., Chittock J. (2016) The effect of an emollient containing urea, ceramide NP, and lactate on skin barrier structure and function in older people with dry skin. Skin Pharmacol Physiol., vol. 29(3), pp. 135–47.

9. Lowe A.J., Su J.C., Allen K.J., Abramson M.J., Cranswick N., Robertson C.F. (2018) A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. Br J Dermatol., vol. 178(1), pp. 19–21.

10. Cork M.J., Danby S.G., Vasilopoulos Y., Hadgraft J. (2009) Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol., vol. 129, pp. 1892–1908.

11. Ong P.Y., Ohtake T., Brandt C., Strickland I. (2002) Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med., vol. 347 (15), pp. 1151–60.

12. Warner M.R., Camisa C. (2013) Topical corticosteroids. In: Wolverton SE (ed.). Comprehensive dermatologic drug therapy, 3rd edn. Philadelphia (PA): Elsevier health sciences, pp. 487–505.

13. Fölster-Holst R., Abeck D., Torrelo A. (2016) Topical hydrocortisone 17-butyrate 21-propionate in the treatment of inflammatory skin diseases: pharmacological data, clinical efcacy, safety and calculation of the therapeutic index. Pharmazie, vol. 71(3), pp. 115–121.

14. Torrelo A. (2017) Methylprednisolone aceponate for atopic dermatitis. Int J Dermatol., vol. 56 (6), pp. 691–697.

15. Titova N. (2019) Recommendations for the safe use of topical glucocorticosteroids in children(in Russian). Pediatrics. Eastern Europe, vol. 7, no 3, pp. 163–169.

16. Mooney E., Rademaker M., Dailey R. (2015) Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement. Australasian Journal of Dermatology, vol. 56, pp. 241–251. doi: 10.1111/ajd.12313

17. Matterne U.1., Böhmer M.M., Weisshaar E., Jupiter A., Carter B., Apfelbacher C.J. (2019) Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema. Cochrane Database Syst Rev., vol. 22, no 1, pp. CD012167.

18. Wernham A.G., Veitch D., Grindlay D.J., Rogers N.K., Harman K. (2019) What’s new in atopic eczema? An analysis of systematic reviews published in 2017. Part 1: treatment and prevention. Clin Exp Dermatol., vol. 44(8), pp. 861–867. doi: 10.1111/ced.14044.

19. Nguyen H.L., Anderson K.R., Tollefson M.M. (2019) New and Emerging Therapies for Pediatric Atopic Dermatitis. Paediatr Drugs., vol. 21(4), pp. 239–260. doi: 10.1007/s40272-019-00342-w.

20. Paller A.S., Tom W.L, Lebwohl M.G. (2016) Efcacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis in children and adults. J Am Acad Dermatol., vol. 75(3), pp. 494–503.e6.

21. Tari H., Holgate S., Pawankar R., Cezmi A.A. (2013) The biodiversity hypothesis and allergic disease: world allergy organization position statement WAO Special Committee on Climate Change and Biodiversity. World Allergy Organization Journal, vol. 6, pp. 1–18.

22. Grice E., Segre J.A. (2011) The skin microbiome. Nat Rev Microbiol., vol. 9, pp. 244–253.

23. Dethlefsen L., Huse S., Sogin M.L., Relman D.A. (2008) The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 165 rRNA sequencing. PLoS Biol., vol. 6, pp. 2383–2400.

24. Prescott S.L., Larcombe D.L., Logan A.C., West C., Burks W. (2017) The skin microbiome: impact of modern environments on skin ecology, barrier integrity, and systemic immune programming. World Allergy Organization Journal, vol. 10, p. 29. doi:10.1186/s40413-017-0160-5

25. Muraro A., Halken S., Arshad S.H., Beyer K., Dubois A.E., Du Toit G. (2014) EAACI food allergy and anaphylaxis guidelines. Primary prevention of food allergy. Allergy, vol. 69, pp. 590–601.

26. Fiocchi A., Pawankar R., Cuello-Garcia C. (2015) World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Probiotics. World Allergy Organ. J., vol. 8(1), p. 4.

27. Notay M., Foolad N., Vaughn A.R., Sivamani R.K. (2017) Probiotics, prebiotics, and synbiotics for the treatment and prevention of adult dermatological diseases. Am J Clin Dermatol, vol. 18, pp. 721–32.

28. Nocerino R., Di Costanzo M., Bedogni G. (2019) Dietary treatment with extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG prevents the occurrence of functional gastrointestinal disorders in children with cow’s milk allergy. J Pediatr., vol. 213, pp. 137–142.e2. doi: 10.1016/j.jpeds.2019.06.004.

29. Drago L., De Vecchi E., Gabrieli A., De Grandi R., Toscano M. (2015) Immunomodulatory effects of Lactobacillus salivarius LS01 and Bifdobacterium breve BR03, alone and in combination, on peripheral blood mononuclear cells of allergic asthmatics. Allergy Asthma Immunol Res., vol. 7, pp. 409–413. doi:10.4168/aair.2015.7.4.409.

30. Capurso L. (2019) Thirty Years of Lactobacillus rhamnosus GG: A Review. J Clin Gastroenterol., vol. 53, pp. 1–41.

31. Mogna L., Del Piano M., Mogna G. (2014) Capability of the two microorganisms Bifdobacterium breve B632 and Bifdobacterium breve BR03 to colonize the intestinal microbiota of children. J Clin Gastroenterol., vol. 48, pp. 37–39.


Для цитирования:

Титова Н.Д. Лечение атопического дерматита у детей: акцент на профилактику и восстановление эпидермального барьера. Рецепт. 2020;24(1):121-130.

For citation:

Titova N. Treatment of Atopic Dermatitis in Children: Focus on Prevention and Restoration of the Epidermal Barrier. Recipe. 2020;24(1):121-130. (In Russ.)

Просмотров: 19

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1993-4882 (Print)
ISSN 2414-2263 (Online)